Inhibitory effects of magnolol and honokiol on human calcitonin aggregation

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Guo, Caiao ^a   Ma, Liang ^a   Zhao, Yudan ^a   Peng, Anlin ^b   Cheng, Biao ^c   Zhou, Qiaoqiao ^a   Zheng, Ling ^d   Huang, Kun ^a,e  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b TONGREN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c CENTRAL HOSPITAL OF WUHAN   (China)

^d WUHAN UNIVERSITY   (China)

^e Centre for Biomedicine Research Wuhan Institute of Biotechnology ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHENYL DERIVATIVE; CALCITONIN; HONOKIOL; LIGNAN; MAGNOLOL; POLYPHENOL; PROTEIN BINDING;

CALORIMETRY; CHEMISTRY; CHINESE MEDICINE; HUMAN; MAGNOLIA; METABOLISM; PHOTON CORRELATION SPECTROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE;

BIPHENYL COMPOUNDS; CALCITONIN; CALORIMETRY; CELL LINE, TUMOR; DYNAMIC LIGHT SCATTERING; HUMANS; LIGNANS; MAGNOLIA; MEDICINE, CHINESE TRADITIONAL; MICROSCOPY, ELECTRON, TRANSMISSION; POLYPHENOLS; PROTEIN BINDING;

EID: 84940874938     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13556     Document Type: Article

References (79)

1. Kelly, J. W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 8, 101-6 (1998).
2. Stefani, M. & Dobson, C. M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med (Berl) 81, 678-99 (2003).
3. DeToma, A. S., Salamekh, S., Ramamoorthy, A. & Lim, M. H. Misfolded proteins in Alzheimer's disease and type II diabetes. Chem Soc Rev 41, 608-21 (2012).
4. Bucciantini, M. et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-11 (2002).
5. Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annual Review of Biochemistry 75, 333-366 (2006).
6. Malchiodi-Albedi, F., Paradisi, S., Matteucci, A., Frank, C. & Diociaiuti, M. Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts. Int J Alzheimers Dis 2011, 906964 (2011).
7. Kamihira, M., Naito, A., Tuzi, S., Nosaka, A. Y. & Saito, H. Conformational transitions and fibrillation mechanism of human calcitonin as studied by high-resolution solid-state 13C NMR. Protein Sci 9, 867-77 (2000).
8. Huang, L., Liu, X., Cheng, B. & Huang, K. How our bodies fight amyloidosis: effects of physiological factors on pathogenic aggregation of amyloidogenic proteins. Arch Biochem Biophys 568, 46-55 (2015).
9. Patel, H. R., Pithadia, A. S., Brender, J. R., Fierke, C. A. & Ramamoorthy, A. In Search of Aggregation Pathways of IAPP and Other Amyloidogenic Proteins: Finding Answers through NMR Spectroscopy. The Journal of Physical Chemistry Letters 5, 1864-1870 (2014).
10. Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95, 6448-53 (1998).
11. Diociaiuti, M. et al. Native metastable prefibrillar oligomers are the most neurotoxic species among amyloid aggregates. Biochim Biophys Acta 1842, 1622-9 (2014).
12. Kotler, S. A., Walsh, P., Brender, J. R. & Ramamoorthy, A. Differences between amyloid-beta aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease. Chem Soc Rev 43, 6692-700 (2014).
13. Ramamoorthy, A. & Lim, M. H. Structural characterization and inhibition of toxic amyloid-beta oligomeric intermediates. Biophys J 105, 287-8 (2013).
14. Naiki, H. & Nagai, Y. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins. J Biochem 146, 751-6 (2009).
15. Mattson, M. P. & Goodman, Y. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res 676, 219-24 (1995).
16. Brender, J. R., Salamekh, S. & Ramamoorthy, A. Membrane Disruption and Early Events in the Aggregation of the Diabetes Related Peptide IAPP from a Molecular Perspective. Accounts of Chemical Research 45, 454-462 (2012).
17. Cheng, B. et al. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases. Biochim Biophys Acta 1830, 4860-71 (2013).
18. Sexton, P. M., Findlay, D. M. & Martin, T. J. Calcitonin. Current Medicinal Chemistry 6, 1067-1093 (1999).
19. Zaidi, M., Inzerillo, A. M., Moonga, B. S., Bevis, P. J. & Huang, C. L. Forty years of calcitonin-where are we now? A tribute to the work of Iain Macintyre, FRS. Bone 30, 655-63 (2002).
20. Schneider, D., Hofmann, M. T. & Peterson, J. A. Diagnosis and treatment of Paget's disease of bone. Am Fam Physician 65, 2069-72 (2002).
21. Arvinte, T., Cudd, A. & Drake, A. F. The structure and mechanism of formation of human calcitonin fibrils. J Biol Chem 268, 6415-22 (1993).
22. Colman, E., Hedin, R., Swann, J. & Orloff, D. A brief history of calcitonin. Lancet 359, 885-6 (2002).
23. Sletten, K., Westermark, P. & Natvig, J. B. Characterization of amyloid fibril proteins from medullary carcinoma of the thyroid. J Exp Med 143, 993-8 (1976).
24. Silver, M. M., Hearn, S. A., Lines, L. D. & Troster, M. Calcitonin and chromogranin A localization in medullary carcinoma of the thyroid by immunoelectron microscopy. J Histochem Cytochem 36, 1031-6 (1988).
25. Andreotti, G. et al. Converting the highly amyloidogenic human calcitonin into a powerful fibril inhibitor by three-dimensional structure homology with a non-Amyloidogenic analogue. J Biol Chem 286, 2707-18 (2011).
26. Cudd, A., Arvinte, T., Das, R. E., Chinni, C. & MacIntyre, I. Enhanced potency of human calcitonin when fibrillation is avoided. J Pharm Sci 84, 717-9 (1995).
27. Yamamoto, Y., Nakamuta, H., Koida, M., Seyler, J. K. & Orlowski, R. C. Calcitonin-induced anorexia in rats: a structure-Activity study by intraventricular injections. Jpn J Pharmacol 32, 1013-7 (1982).
28. Feletti, C. & Bonomini, V. Effect of calcitonin on bone lesions in chronic dialysis patients. Nephron 24, 85-8 (1979).
29. Zhang, M. et al. Nanomaterials for reducing amyloid cytotoxicity. Adv Mater 25, 3780-801 (2013).
30. Elgersma, R. C., Posthuma, G., Rijkers, D. T. & Liskamp, R. M. Backbone-modified amylin derivatives: implications for amyloid inhibitor design and as template for self-Assembling bionanomaterials. J Pept Sci 13, 709-16 (2007).
31. DeToma, A. S. et al. Synthetic Flavonoids, Aminoisoflavones: Interaction and Reactivity with Metal-Free and Metal-Associated Amyloid-beta Species. Chem Sci 5, 4851-4862 (2014).
32. Savelieff, M. G. et al. A small molecule that displays marked reactivity toward copper-versus zinc-Amyloid-beta implicated in Alzheimer's disease. Chem Commun (Camb) 50, 5301-3 (2014).
33. Choi, J. S., Braymer, J. J., Nanga, R. P., Ramamoorthy, A. & Lim, M. H. Design of small molecules that target metal-A{beta} species and regulate metal-induced A{beta} aggregation and neurotoxicity. Proc Natl Acad Sci USA 107, 21990-5 (2010).
34. Jiao, L. et al. Proanthocyanidins are the major anti-diabetic components of cinnamon water extract. Food Chem Toxicol 56, 398-405 (2013).
35. Cheng, B. et al. Salvianolic acid B inhibits the amyloid formation of human islet amyloid polypeptide and protects pancreatic beta-cells against cytotoxicity. Proteins 81, 613-21 (2013).
36. Wang, L. et al. Natural product agonists of peroxisome proliferator-Activated receptor gamma (PPARgamma): a review. Biochem Pharmacol 92, 73-89 (2014).
37. Shen, J. L. et al. Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders. Molecules 15, 6452-65 (2010).
38. Fujita, S. & Taira, J. Biphenyl compounds are hydroxyl radical scavengers: their effective inhibition for UV-induced mutation in Salmonella typhimurium TA102. Free Radic Biol Med 17, 273-7 (1994).
39. Liu, Y. et al. The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy. Sci Rep 3, 3098 (2013).
40. Reches, M., Porat, Y. & Gazit, E. Amyloid fibril formation by pentapeptide and tetrapeptide fragments of human calcitonin. J Biol Chem 277, 35475-80 (2002).
41. Bernaskova, M. et al. Synthesis of tetrahydrohonokiol derivates and their evaluation for cytotoxic activity against CCRF-CEM leukemia, U251 glioblastoma and HCT-116 colon cancer cells. Molecules 19, 1223-37 (2014).
42. Lin, Y. R., Chen, H. H., Ko, C. H. & Chan, M. H. Effects of honokiol and magnolol on acute and inflammatory pain models in mice. Life Sci 81, 1071-8 (2007).
43. Munroe, M. E., Arbiser, J. L. & Bishop, G. A. Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J Immunol 179, 753-63 (2007).
44. Lin, Y. R., Chen, H. H., Ko, C. H. & Chan, M. H. Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage. Eur J Pharmacol 537, 64-9 (2006).
45. Hoi, C. P., Ho, Y. P., Baum, L. & Chow, A. H. Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta-Amyloid-induced toxicity in PC12 cells. Phytother Res 24, 1538-42 (2010).
46. Lee, Y. J. et al. Ethanol Extract of Magnolia officinalis Prevents Lipopolysaccharide-Induced Memory Deficiency via Its Antineuroinflammatory and Antiamyloidogenic Effects. Phytotherapy Research 27, 438-447 (2013).
47. Porat, Y., Abramowitz, A. & Gazit, E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 67, 27-37 (2006).
48. Shoval, H. et al. Polyphenol-induced dissociation of various amyloid fibrils results in a methionine-independent formation of ROS. Biochim Biophys Acta 1784, 1570-7 (2008).
49. Bieschke, J. et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 107, 7710-5 (2010).
50. Popovych, N. et al. Site specific interaction of the polyphenol EGCG with the SEVI amyloid precursor peptide PAP(248-286). J Phys Chem B 116, 3650-8 (2012).
51. Suzuki, Y., Brender, J. R., Hartman, K., Ramamoorthy, A. & Marsh, E. N. Alternative pathways of human islet amyloid polypeptide aggregation distinguished by (19)f nuclear magnetic resonance-detected kinetics of monomer consumption. Biochemistry 51, 8154-62 (2012).
52. Meng, F., Abedini, A., Plesner, A., Verchere, C. B. & Raleigh, D. P. The flavanol (?)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry 49, 8127-33 (2010).
53. Hyung, S. J. et al. Insights into antiamyloidogenic properties of the green tea extract (?)-epigallocatechin-3-gallate toward metalassociated amyloid-beta species. Proc Natl Acad Sci U S A 110, 3743-8 (2013).
54. Mecocci, P. & Polidori, M. C. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim Biophys Acta 1822, 631-8 (2012).
55. Huang, R. et al. NMR characterization of monomeric and oligomeric conformations of human calcitonin and its interaction with EGCG. J Mol Biol 416, 108-20 (2012).
56. Ma, Q. et al. The contrasting effect of macromolecular crowding on amyloid fibril formation. PLoS One 7, e36288 (2012).
57. Glabe, C. G. Structural classification of toxic amyloid oligomers. J Biol Chem 283, 29639-43 (2008).
58. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-9 (2003).
59. Yang, F. et al. Binding of ferulic acid to cytochrome c enhances stability of the protein at physiological pH and inhibits cytochrome c-induced apoptosis. Chem Biol Interact 170, 231-43 (2007).
60. Chi, E. Y., Krishnan, S., Randolph, T. W. & Carpenter, J. F. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20, 1325-36 (2003).
61. Bulic, B. et al. Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl 48, 1740-52 (2009).
62. Baptista, F. I., Henriques, A. G., Silva, A. M., Wiltfang, J. & da Cruz e Silva, O.A. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. ACS Chem Neurosci 5, 83-92 (2014).
63. Yamin, G., Ruchala, P. & Teplow, D. B. A peptide hairpin inhibitor of amyloid beta-protein oligomerization and fibrillogenesis. Biochemistry 48, 11329-31 (2009).
64. Shaltiel-Karyo, R. et al. Inhibiting alpha-synuclein oligomerization by stable cell-penetrating beta-synuclein fragments recovers phenotype of Parkinson's disease model flies. PLoS One 5, e13863 (2010).
65. Wu, C., Lei, H. X., Wang, Z. X., Zhang, W. & Duan, Y. Phenol red interacts with the protobril-like oligomers of an amyloidogenic hexapeptide NFGAIL through both hydrophobic and aromatic contacts. Biophysical Journal 91, 3664-3672 (2006).
66. Ahmad, E. et al. A mechanistic approach for islet amyloid polypeptide aggregation to develop anti-Amyloidogenic agents for type-2 diabetes. Biochimie 93, 793-805 (2011).
67. Itoh-Watanabe, H. et al. Role of aromatic residues in amyloid fibril formation of human calcitonin by solid-state 13C NMR and molecular dynamics simulation. Phys Chem Chem Phys 15, 8890-901 (2013).
68. Fullmer, M. J., Haltiwanger, R. C., Troupe, N. & Eggleston, D. S. Honokiol. Acta Crystallographica Section C 50, 1966-1967 (1994).
69. Wang, Y., Cheng, M.-C., Lee, J.-S. & Chen, F.-C. Molecular and Crystal Structure of Magnolol-C18H18O2. Journal of the Chinese Chemical Society 30, 215-221 (1983).
70. Tufail, S. et al. Amyloid form of ovalbumin evokes native antigen-specific immune response in the host: prospective immunoprophylactic potential. J Biol Chem 290, 4131-48 (2015).
71. Soong, R., Brender, J. R., Macdonald, P. M. & Ramamoorthy, A. Association of highly compact type II diabetes related islet amyloid polypeptide intermediate species at physiological temperature revealed by diffusion NMR spectroscopy. J Am Chem Soc 131, 7079-85 (2009).
72. Ghosh, A. et al. Self-Assembly of a nine-residue amyloid-forming peptide fragment of SARS corona virus E-protein: mechanism of self aggregation and amyloid-inhibition of hIAPP. Biochemistry 54, 2249-61 (2015).
73. Smith, P. E., Brender, J. R. & Ramamoorthy, A. Induction of negative curvature as a mechanism of cell toxicity by amyloidogenic peptides: the case of islet amyloid polypeptide. J Am Chem Soc 131, 4470-8 (2009).
74. Saborio, G. P., Permanne, B. & Soto, C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411, 810-3 (2001).
75. Herva, M. E. et al. Anti-Amyloid compounds inhibit alpha-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA). J Biol Chem 289, 11897-905 (2014).
76. Zhang, X. et al. Porcine islet amyloid polypeptide fragments are refractory to amyloid formation. FEBS Lett 585, 71-7 (2011).
77. Gong, H. et al. Effects of several quinones on insulin aggregation. Sci Rep 4, 5648 (2014).
78. Gong, H. et al. Bisphenol A accelerates toxic amyloid formation of human islet amyloid polypeptide: a possible link between bisphenol A exposure and type 2 diabetes. PLoS One 8, e54198 (2013).
79. Cheng, B. et al. Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide. Biochem Biophys Res Commun 419, 495-9 (2012).